Stay updated with breaking news from Dark Antigen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared,...
Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit Oxford and London, UK – 09 June 2021. Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) and Dark Antigen™ discovery pl...
Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies 15th January 2021 Boehringer Ingelheim has entered a strategic collaboration with UK biotech Enara Bio to research and discover novel targeted cancer immunotherapies. The agreement will leverage Enara’s Dark Antigen discovery platform to identify and validate novel dark antigens in up to three tumour types across the lung and gastrointestinal cancer areas. Dark antigens are a new class of cancer-associated antigens that derive from genomic dark matter – the portion of the human genome that is normally not ex...
(2) Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim's position in the cancer vaccine and T-cell engager spaces Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio's EDAPT platform and Dark Antigen discovery work and supports ongoing cell therapy based therapeutic approach Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and...